We got all of the Industry Focus hosts in a room to talk about the major stories and stocks of 2018, and what to watch for in 2019. In this episode, the gang breaks down some cautionary tales from 2018, some stories investors might have missed, and the best turnarounds from the past year.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

We got all of the Industry Focus hosts in a room to talk about the major stories and stocks of 2018, and what to watch for in 2019. In this episode, the gang breaks down what defined 2018 in each sector, the best debuts of 2018, and the leaders that shined in the past year.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

We got all of the Industry Focus hosts in a room to talk about the major stories and stocks of 2018, and what to watch for in 2019. In this episode, the gang breaks down what defined 2018 in each sector, the best debuts of 2018, and the leaders that shined in the past year.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

2018 hasn't exactly been a banner year for the stock market, but it's been particularly rough for video game publishers like Electronic Arts and Activision Blizzard -- both stocks are down 25% year-to-date. On this episode we explain why these stocks have fallen so much and why 2019 could be kinder to them.

Stocks: EA, ATVI, TTWO

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

2018 hasn't exactly been a banner year for the stock market, but it's been particularly rough for video game publishers like Electronic Arts and Activision Blizzard -- both stocks are down 25% year-to-date. On this episode we explain why these stocks have fallen so much and why 2019 could be kinder to them.

Stocks: EA, ATVI, TTWO

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

Motley Fool analysts Jason Hall and Nick Sciple break down the recent news in the oil market coming out of OPEC and break down the important industries and trends affecting solar energy today.

Stocks Mentioned:TSLA, FSLR, HQCL, JKS, CSIQ, SPWR, SEDG, ENPH, NEP, BEP, PEGI, TERP

Stories Mentioned:

Jason's Primer on Solar Energy Investing

What is the Duck Curve?

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

Motley Fool analysts Jason Hall and Nick Sciple break down the recent news in the oil market coming out of OPEC and break down the important industries and trends affecting solar energy today.

Stocks Mentioned:TSLA, FSLR, HQCL, JKS, CSIQ, SPWR, SEDG, ENPH, NEP, BEP, PEGI, TERP

Stories Mentioned:

Jason's Primer on Solar Energy Investing

What is the Duck Curve?

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

China’s biotech industry is booming. Driven by vast government funding and Western partnerships, the country is introducing new commercial drugs at a faster pace than ever before. But could controversial topics such as human genetic engineering derail its accelerated growth? Shannon Jones and special guest Simon Erickson put this fast-growing field under the microscope, and they share their thoughts about Celgene (Nasdaq: CELG), BeiGene (Nasdaq: BGNE), and Legend Biotech.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

China’s biotech industry is booming. Driven by vast government funding and Western partnerships, the country is introducing new commercial drugs at a faster pace than ever before. But could controversial topics such as human genetic engineering derail its accelerated growth? Shannon Jones and special guest Simon Erickson put this fast-growing field under the microscope, and they share their thoughts about Celgene (Nasdaq: CELG), BeiGene (Nasdaq: BGNE), and Legend Biotech.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]

While a new slate of Roomba offerings drives accelerating top and bottom line growth for the company, rising tariffs on iRobot’s China-made vacuums have investors worried about near-term profitability and sales. We break down the latest results and outlook for the world’s leading consumer robot company. Stock: IRBT

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn

Or, reach us by email @ [email protected]